Induction of TAp63 by histone deacetylase inhibitors

Biochemical and Biophysical Research Communications

Volumn 391, Issue 4, 2010, Pages 1748-1751

  Sayan, Berna S ^a   Yang, Ai Li ^a   Conforti, Franco ^a,c   Bernardini, Sergio ^c   Tucci, Paola ^b   Vasa Nicotera, Mariuca ^a   Knight, Richard A ^a   Melino, Gerry ^a,b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Apoptosis; Cell death; Chemosensitivity; HDAC inhibitors; LBH589; p63; TSA

Indexed keywords

PANOBINOSTAT; PROTEIN P53; PROTEIN P63; TAP63 PROTEIN; TRICHOSTATIN A; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HCT116; CHEMOSENSITIVITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION;

CELL LINE, TUMOR; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS;

EID: 74449088062     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.12.147     Document Type: Article

References (23)

1. Belyi V.A., and Levine A.J. One billion years of p53/p63/p73 evolution. Proc. Natl. Acad. Sci. USA 106 (2009) 17609-17610
2. Candi E., Rufini A., Terrinoni A., Dinsdale D., Ranalli M., Paradisi A., De Laurenzi V., Spagnoli L.G., Catani M.V., Ramadan S., Knight R.A., and Melino G. Differential roles of p63 isoforms in epidermal development: selective genetic complementation in p63 null mice. Cell Death Differ. 13 (2006) 1037-1047
3. Laurikkala J., Mikkola M.L., James M., Tummers M., Mills A.A., and Thesleff I. p63 regulates multiple signalling pathways required for ectodermal organogenesis and differentiation. Development 133 (2006) 1553-1563
4. Yang A., Kaghad M., Wang Y., Gillett E., Fleming M.D., Dotsch V., Andrews N.C., Caput D., and McKeon F. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2 (1998) 305-316
5. Jacobs W.B., Govoni G., Ho D., Atwal J.K., Barnabe-Heider F., Keyes W.M., Mills A.A., Miller F.D., and Kaplan D.R. p63 is an essential proapoptotic protein during neural development. Neuron 48 (2005) 743-756
6. Jacobs W.B., Kaplan D.R., and Miller F.D. The p53 family in nervous system development and disease. J. Neurochem. 97 (2006) 1571-1584
7. Suh E.K., Yang A., Kettenbach A., Bamberger C., Michaelis A.H., Zhu Z., Elvin J.A., Bronson R.T., Crum C.P., and McKeon F. p63 protects the female germ line during meiotic arrest. Nature 444 (2006) 624-628
8. Gonfloni S., Di Tella L., Caldarola S., Cannata S.M., Klinger F.G., Di Bartolomeo C., Mattei M., Candi E., De Felici M., Melino G., and Cesareni G. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nat. Med. 15 (2009) 1179-1185
9. Yang A., Schweitzer R., Sun D., Kaghad M., Walker N., Bronson R.T., Tabin C., Sharpe A., Caput D., Crum C., and McKeon F. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398 (1999) 714-718
10. Gressner O., Schilling T., Lorenz K., Schulze Schleithoff E., Koch A., Schulze-Bergkamen H., Maria Lena A., Candi E., Terrinoni A., Valeria Catani M., Oren M., Melino G., Krammer P.H., Stremmel W., and Muller M. TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J. 24 (2005) 2458-2471
11. Melino G., Lu X., Gasco M., Crook T., and Knight R.A. Functional regulation of p73 and p63: development and cancer. Trends Biochem. Sci. 28 (2003) 663-670
12. Sayan B.S., Sayan A.E., Yang A.L., Aqeilan R.I., Candi E., Cohen G.M., Knight R.A., Croce C.M., and Melino G. Cleavage of the transactivation-inhibitory domain of p63 by caspases enhances apoptosis. Proc. Natl. Acad. Sci. USA 104 (2007) 10871-10876
13. Roth S.Y., Denu J.M., and Allis C.D. Histone acetyltransferases. Annu. Rev. Biochem. 70 (2001) 81-120
14. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6 (2006) 38-51
15. Baylin S.B., and Schuebel K.E. Genomic biology: the epigenomic era opens. Nature 448 (2007) 548-549
16. Lane A.A., and Chabner B.A. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 27 (2009) 5459-5468
17. Bolden J.E., Peart M.J., and Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5 (2006) 769-784
18. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1 (2001) 194-202
19. Frew A.J., Johnstone R.W., and Bolden J.E. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett. 280 (2009) 125-133
20. Stimson L., Wood V., Khan O., Fotheringham S., and La Thangue N.B. HDAC inhibitor-based therapies and haematological malignancy. Ann. Oncol. 20 (2009) 1293-1302
21. Chikh A., Sayan E., Thibaut S., Lena A.M., DiGiorgi S., Bernard B.A., Melino G., and Candi E. Expression of GATA-3 in epidermis and hair follicle: relationship to p63. Biochem. Biophys. Res. Commun. 361 (2007) 1-6
22. Sayan A.E., Sayan B.S., Findikli N., and Ozturk M. Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells. Oncogene 20 (2001) 5111-5117
23. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 280 (2009) 233-241